THC Global Group Limited (ASX:THC) (OTCMKTS:HDRPF) (FRA:9TH) operates under a 'Farm to Pharma' pharmaceutical model, now holding all three key cannabis licences being a Cannabis Research Licence, a Medicinal Cannabis Licence (Cultivation), and a Manufacture Licence through its domestic medicinal cannabis subsidiaries THC Pharma and Canndeo. THC Global has secured a significant cannabis growing capacity over multiple cultivation projects and owns a pharmaceuticals bio-manufacturing facility with attached testing and product development laboratory. THC Global is in prime position to commence medicinal cannabis production to service both domestic patients and the global export market. THC Global is active globally with operations in Australia, New Zealand, and Canada and partnerships across Europe, Asia, and the Middle East. In addition to its core Australian medicinal cannabis assets, THC Global has a significant Canadian presence – both in cannabis and in hydroponics equipment. THC Global's Canadian cannabis operation, Vertical Canna, holds property in Nova Scotia, Canada being developed into a large scale cannabis production site. THC Global's hydroponics equipment division, Crystal Mountain, is a revenue generating manufacturer, wholesaler, and retailer of hydroponic equipment and supplies.
THC Global Group Limited
ASX:THC ISIN:AU000000THC4
News
The Hydroponics Company Limited (ASX:THC) (OTCMKTS:HDRPF), Australia's leading medicinal cannabis company advises that THC's wholly owned subsidiary, Canndeo Limited, has released its first medicinal cannabis products, imported from the Company's European strategic alliance partner, Endoca.
The Hydroponics Company Limited (ASX:THC) (OTCMKTS:HDRPF), Australia's leading medicinal cannabis company and Biofloral Inc, a Canadian east coast hydroponics company, have chosen to work together to benefit from each other's IP and distribution networks. The proposed acquisition of BioFloral (ASX- 24 January 2018) is not proceeding.
The Hydroponics Company Limited (ASX:THC) (OTCMKTS:HDRPF), Australia's leading Medicinal Cannabis company provides the enclosed Company Presentation updated to July 2018 in accordance with ASX Listing Rule 3.1.
The Hydroponics Company Limited (ASX:THC) (OTCMKTS:HDRPF), Australia's leading Medicinal Cannabis company advises that the conditions precedent have been met for the lease of a Northern NSW property to be used for the growing of medicinal cannabis strains as a primary source for its own manufacture within its Southport manufacturing facility.
The Hydroponics Company Limited (ASX:THC) (OTCMKTS:HDRPF), Australia's leading Medicinal Cannabis company, provides the following update with respect to a revaluation of the Company's Southport pharmaceutical manufacturing facility of $14.58 million with an unmatched domestic manufacturing capability.
The Hydroponics Company Limited (ASX:THC) (OTCMKTS:HDRPF), Australia's leading Medicinal Cannabis company, after an extensive executive search, has appointed Ken Charteris as Group Chief Executive Officer, effective 11 July 2018.
The Hydroponics Company Limited (ASX:THC) (OTCMKTS:HDRPF), Australia's leading Medicinal Cannabis Company has signed a binding Letter of Intent with Endoca BV.
The Hydroponics Company Limited (ASX:THC), Australia's leading medicinal cannabis company1, provides the following update with respect to the Company's North American development plans.
The Hydroponics Company Limited (ASX:THC) is pleased to advise THC Pharma Pty Ltd, a wholly owned subsidiary of THC, has concluded a Letter of Intent with Ascent Industries Corp.
41,664 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 115) (Last 30 Days: 512) (Since Published: 41664)